Y-mAbs Therapeutics, Inc.’s YMAB share price has dipped by 7.47%, which has investors questioning if this is right time to ...

We've discovered 3 warning signs about Y-mAbs Therapeutics. View them for free. A look at the shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) can tell us which group is most powerful. And the ...

Y-mAbs Therapeutics (NASDAQ:YMAB) lost ~6% on Tuesday after Bank of America downgraded the cancer drug developer to ...

Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at ...

Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma. Y-mAbs Therapeutics, Inc. announced that the first patient has ...

YMAB's naxitamab shows a 50% overall response rate in phase 2 trials for high-risk neuroblastoma, supporting its ongoing commercialization efforts. The SADA platform, targeting GD2 and CD38, is ...

Y-mAbs Therapeutics (YMAB) announced that the first patient has been administered both the first protein dose and the Lu-DOTA imaging dose in ...

The market expects Y-mAbs Therapeutics, Inc. (YMAB) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024.

1 Day YMAB 3.30% DJIA -1.33% Russell 2K 0.00% Health Care/Life Sciences -0.86% ...

During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:YMAB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a ...

Lockheed Martin ( LMT) was upgraded to Outperform from a previous investment rating of Neutral by analysts at ...